Kiniksa Pharmaceuticals, Ltd..
KNSA.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients with debilitating diseases with unmet medical need. The company's pipeline includes product candidates in various stages of clinical deve...Show More
Better Health for All
-30
Kiniksa Pharmaceuticals' core product, ARCALYST, is an FDA-approved treatment for rare, debilitating diseases such as recurrent pericarditis, Cryopyrin-Associated Periodic Syndromes (CAPS), and Deficiency of Interleukin-1 Receptor Antagonist (DIRA).
1
It is the first and only FDA-approved therapy for recurrent pericarditis, demonstrating an exceptional health benefit.
2
The company's mission is centered on developing life-changing therapies for unmet medical needs, with no evidence of revenue from harmful products. However, ARCALYST carries significant safety risks, including reported life-threatening infections and death, and a potential increased risk of cancer.
3
The company discloses these risks in its safety information and has a 24-hour reporting obligation for safety issues.
4
Kiniksa offers financial assistance programs for ARCALYST, including a Copay Assistance Program that can reduce costs to as little as $0 per month for eligible commercially insured patients, a Quick Start Program for up to 60 days, and a Patient Assistance Program for up to 12 months for those with limited or no coverage.
5
The company's Named Patient Program aims to expand access to ARCALYST in countries where it is not commercially available, and its Managed Access Programs provide investigational medicines for serious conditions.
6
Kiniksa invests in R&D, with KPL-387 in Phase 2/3 clinical trials and KPL-1161 in preclinical development.
7
The company is committed to minimizing environmental damage.
8
Kiniksa provides health and welfare benefits and a 401(k) plan for employees.
9
It also provides injection training and ongoing education for patients and healthcare professionals.
10
The company conducts clinical trials and Managed Access Programs, requiring regulatory and ethics committee approvals, patient consent, and safety reporting.
11
Kiniksa respects personal data and complies with applicable privacy laws, collecting only minimum necessary data for legitimate business purposes.
12
The company's intellectual property includes patents, but there is no specific evidence of flexibility in patent enforcement for global health needs.
13
There is no evidence of specific health equity programs beyond general access initiatives, or significant investment in preventative health measures.
Fair Money & Economic Opportunity
0
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company focused on developing and commercializing therapeutic medicines.
1
The 'Fair Money & Economic Opportunity' value assesses financial institutions and their impact on financial inclusion, lending, and wealth building. Kiniksa's core business does not involve offering lending, deposit, or other financial services to consumers.
2
While the company provides patient assistance programs (e.g., Commercial Copay Assistance, Quick Start, Patient Assistance) to reduce the cost of its medical treatments for eligible patients,
3
these initiatives relate to access to pharmaceutical products, not financial services or economic opportunity as defined by the rubric's KPIs. Therefore, no KPIs under this value are applicable or can be scored based on the provided evidence.
Fair Pay & Worker Respect
0
Insufficient evidence to determine a value score for Kiniksa Pharmaceuticals, Ltd. regarding Fair Pay & Worker Respect. No articles or relevant information found. A neutral score of 0 is assigned.
Materiality Analysis: Company Summary (75-100 words): Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on developing and commercializing therapies for unmet medical needs, primarily in cardiovascular and inflammatory diseases. Their lead product, ARCALYST, treats recurrent pericarditis. Other pipeline products target prurigo nodularis and advanced recurrent pericarditis. The company conducts clinical trials and preclinical research. While headquartered in London, their operations likely involve manufacturing, research, and commercial activities across multiple geographic locations. Kiniksa transitioned from Kiniksa Pharmaceuticals, Ltd in June 2024.
Peer Comparison (50-75 words): Compared to other biopharmaceutical companies, Kiniksa's impact on "Fair Pay & Worker Respect" is generally similar. The industry requires skilled labor and adherence to safety regulations in research and manufacturing. Performance depends on compensation practices, workplace safety, union relations, and labor-violation records, aligning with industry norms.
Materiality Assessment (1-2 clear sentences): The business model is fundamentally neutral regarding "Fair Pay & Worker Respect," with medium materiality, as fair labor practices are essential for attracting and retaining talent and maintaining operational integrity but are not directly linked to the core product or service.
Detailed Rationale (150-200 words): Kiniksa's operations involve research, development, manufacturing, and commercialization, all of which require a skilled workforce. Fair wages, safe working conditions, and respect for worker rights are crucial for attracting and retaining qualified personnel, ensuring ethical conduct, and mitigating legal and reputational risks. While the company's core business is developing and selling pharmaceuticals, its labor practices directly impact its operational efficiency and sustainability. The absence of fair labor practices could lead to employee dissatisfaction, high turnover, and potential legal issues, affecting the company's ability to innovate and deliver its products. Supply chain considerations are less significant for this value, as it focuses primarily on Kiniksa's direct employees.
Value Interaction Notes (if applicable, 25-50 words): No significant tensions between values are apparent. Strong performance on "Fair Pay & Worker Respect" generally supports positive performance across other values related to ethical conduct and social responsibility.
Scoring Boundary Flags (if applicable, 25-50 words): Scores below 3 or above 8 would be illogical. A score below 3 would suggest systemic labor violations, which would be highly unlikely for a publicly traded biopharmaceutical company. A score above 8 would imply exceptional performance far exceeding industry norms, which is not substantiated by available information.
Fair Trade & Ethical Sourcing
-10
As of June 4, 2024, Kiniksa's global compliance functions have not received any complaints or notifications related to modern slavery through its hotline or other mechanisms.
1
The company screens public records and watchlists of prospective suppliers to identify issues such as reported instances of modern slavery.
2
Honest & Fair Business
0
Kiniksa Pharmaceuticals has a formal whistleblower policy, including an independent third-party hotline (EthicsPoint) available 24/7, which allows for anonymous reporting where permitted by local law, and emphasizes non-retaliation for good-faith reporting.
1
The company also has a strong anti-bribery and anti-corruption policy, which includes FCPA compliance, and states it does not pay or accept bribes or kickbacks.
2
It exercises due diligence and carefully monitors third parties, screening them particularly in high-corruption countries.
3
The Anti-Bribery and Anti-Corruption Policy is reviewed and approved by the Board of Directors and its Audit Committee.
4
Audits of the company’s sites, operating units, and contractors may be conducted internally or externally by retained third parties to ensure policy compliance.
5
However, the company filed a supplement to a definitive proxy statement on May 9, 2025, to correct errors in executive compensation data due to an administrative omission.
6
The company states that approximately 50% of ethical claims are independently verified with a standardized scope.
Kind to Animals
0
No relevant data was found in the provided articles to assess Kiniksa Pharmaceuticals, Ltd. against the 'Kind to Animals' value. All articles resulted in 404 errors, indicating that the requested content was unavailable.
1
No War, No Weapons
0
No evidence available to assess Kiniksa Pharmaceuticals, Ltd. on No War, No Weapons.
Planet-Friendly Business
-20
In 2022, the company's Scope 1 GHG emissions were 287 metric tons CO2e, with a projected decline to 276 metric tons CO2e in 2023.
1
In 2022, 22% of operational energy consumption was sourced from renewables, with a projected increase to 28% in 2023.
2
Respect for Cultures & Communities
0
No evidence available to assess Kiniksa Pharmaceuticals, Ltd. on Respect for Cultures & Communities.
Safe & Smart Tech
-40
The company has not experienced a material data breach or failure of its cybersecurity program.
1
It has not experienced any documented incidents of unauthorized data use.
2
However, its privacy policy states that user rights to access, change, or move clinical trial information may be limited to ensure research reliability and accuracy.
3
The company performs regular vulnerability scans and penetration tests, and uses various tools and methodologies to test cybersecurity defenses.
4
It retains personal data only as long as necessary, but also states that deidentified data may be used indefinitely.
5
The company acknowledges being subject to GDPR, CCPA, HIPAA, and other regulations, but current industry practices, which the company is part of, are noted to violate HIPAA, FDA's 21 CFR Part 11, and GDPR.
6
Zero Waste & Sustainable Products
0
No specific, quantitative data or qualitative information regarding waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certifications, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education was found in the provided articles.
1
The articles primarily address the company's code of conduct, compliance, ethics, and carbon footprint, without detailing zero waste or sustainable product metrics.